Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Invested Capital (2016 - 2025)

Historic Invested Capital for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $313.7 million.

  • Rocket Pharmaceuticals' Invested Capital fell 488.28% to $313.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.7 million, marking a year-over-year decrease of 488.28%. This contributed to the annual value of $463.2 million for FY2024, which is 595.65% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Invested Capital stood at $313.7 million, which was down 488.28% from $354.2 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Invested Capital peaked at $541.1 million during Q3 2023, and registered a low of $313.7 million during Q3 2025.
  • For the 5-year period, Rocket Pharmaceuticals' Invested Capital averaged around $429.8 million, with its median value being $441.5 million (2024).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Invested Capital skyrocketed by 10081.71% in 2021, and later plummeted by 3905.39% in 2024.
  • Rocket Pharmaceuticals' Invested Capital (Quarter) stood at $454.7 million in 2021, then increased by 7.69% to $489.7 million in 2022, then increased by 0.59% to $492.6 million in 2023, then fell by 5.96% to $463.2 million in 2024, then crashed by 32.29% to $313.7 million in 2025.
  • Its last three reported values are $313.7 million in Q3 2025, $354.2 million for Q2 2025, and $412.1 million during Q1 2025.